SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: leigh aulper who wrote (1213)7/1/2003 7:07:38 PM
From: Cacaito  Read Replies (1) of 1386
 
Very important from today pr release:..."The primary endpoint for the study will be patient outcome as measured on the Glasgow Outcome Scale - Extended (GOSE) six months after injury."

Usually a drug will be approved based on the agreement Company/Fda on the "1ry endpoint", this is the first time I read that "GOSE at 6 month" IS THE 1RY endpoint, therefore it is not mortality (a tougher endpoint).

The 1ry endpoint is reasonable, but nevertheless it is an achievement of Pars Executives that they were able to negotiate, convince and get the stated 1ry outcome.

Much less risk to hold Pars.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News